BACKGROUND: The European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) was evaluated for its psychometric properties in a sample of cancer patients from the culturally distinct South Asian subcontinent, which accounts for a significant proportion of the global cancer burden. METHODS: Psychometric testing assessed the hypothesised scale structure, internal consistency, content and construct validity, and acceptability of the Sinhala version of the QLQ-C30 independently in two heterogeneous groups of cancer patients at pretreatment (N = 489) and during treatment (N = 343). RESULTS: Qualitative feedback from an expert panel assessing content validity recommended measuring family support during illness as an additional, culturally-relevant dimension of health-related quality of life (HRQL). Compliance was high (100%), with little missing data (0.11%). Multitrait scaling results supported the scale structure of the QLQ-C30, with the exception of the cognitive functioning scale, which was also the only scale that did not meet the 0.70 internal consistency criteria in either sample. Interscale correlations were of a moderate size, with conceptually related scales showing higher correlations. All scales were able to discriminate clearly between pre- and current treatment patients (P < 0.01), although results were less consistent when comparing groups formed on the basis of age and disease stage. CONCLUSIONS: Overall psychometric results confirmed the QLQ-C30 as a reliable and valid questionnaire for assessing HRQL of cancer patients in Sri Lanka.
BACKGROUND: The European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) was evaluated for its psychometric properties in a sample of cancerpatients from the culturally distinct South Asian subcontinent, which accounts for a significant proportion of the global cancer burden. METHODS: Psychometric testing assessed the hypothesised scale structure, internal consistency, content and construct validity, and acceptability of the Sinhala version of the QLQ-C30 independently in two heterogeneous groups of cancerpatients at pretreatment (N = 489) and during treatment (N = 343). RESULTS: Qualitative feedback from an expert panel assessing content validity recommended measuring family support during illness as an additional, culturally-relevant dimension of health-related quality of life (HRQL). Compliance was high (100%), with little missing data (0.11%). Multitrait scaling results supported the scale structure of the QLQ-C30, with the exception of the cognitive functioning scale, which was also the only scale that did not meet the 0.70 internal consistency criteria in either sample. Interscale correlations were of a moderate size, with conceptually related scales showing higher correlations. All scales were able to discriminate clearly between pre- and current treatment patients (P < 0.01), although results were less consistent when comparing groups formed on the basis of age and disease stage. CONCLUSIONS: Overall psychometric results confirmed the QLQ-C30 as a reliable and valid questionnaire for assessing HRQL of cancerpatients in Sri Lanka.
Authors: A Montazeri; I Harirchi; M Vahdani; F Khaleghi; S Jarvandi; M Ebrahimi; M Haji-Mahmoodi Journal: Qual Life Res Date: 2000-03 Impact factor: 4.147
Authors: K Kobayashi; F Takeda; S Teramukai; I Gotoh; H Sakai; S Yoneda; Y Noguchi; H Ogasawara; K Yoshida Journal: Eur J Cancer Date: 1998-05 Impact factor: 9.162
Authors: A Montazeri; I Harirchi; M Vahdani; F Khaleghi; S Jarvandi; M Ebrahimi; M Haji-Mahmoodi Journal: Support Care Cancer Date: 1999-11 Impact factor: 3.603
Authors: K Bjordal; E Hammerlid; M Ahlner-Elmqvist; A de Graeff; M Boysen; J F Evensen; A Biörklund; J R de Leeuw; P M Fayers; M Jannert; T Westin; S Kaasa Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Dakshitha P Wickramasinghe; Praveen Dayasena; Sanjeewa Seneviratne; Dharmabandhu N Samarasekera Journal: Asian Pac J Cancer Prev Date: 2020-01-01